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Scardiac arrest (OHCA) patients, but data on the long-term survival are scarce. We
performed a study to assess long-term survival in OHCA patients managed with CA
on admission and PCI if indicated and to compare survival between patients with and
without acute myocardial infarction (AMI).
Methods: Retrospective single-centre study including patients 18 y.o. resuscitated
from an OHCA without an obvious non-cardiac cause. AMI was diagnosed angio-
graphically as lesions suggestive of ruptured plaques with fresh thrombus and critical
stenosis easily crossed by an angioplasty wire. Survival was recorded at discharge and
5-years survival probability was estimated by Kaplan-Meier survival curves. Data are
expressed as numbers (percentages) and median (interquartile range-IQR).
Results: 300 comatose patients aged 56 (48-67) were included from 2002 to 2011.
130 patients (43%) had ventricular ﬁbrillation, 116 (39%) asystole, 54 (18%) had
other/unknown initial rhythm. All patients had CA on admission and 93 (31%) had an
AMI. PCI was attempted in 85 (91%) of AMI patients, successful in 79. Therapeutic
hypothermia was performed in 256 (84%) patients. Survival at discharge was 32.3%
(97/300). After discharge, 5-year probability of survival was 81.75.4%. Probability
of survival from admission to 5 years was 26.2%2.8%. AMI patients had better
survival at discharge, 40.8% (38/93) versus 28.5% (59/207) in non-AMI, p¼0.047.
Probability of survival from discharge to 5 years in AMI patients was 92.2%5.4%
versus 73.48.6% in non-AMI, hazard ratio (HR)¼2.7, conﬁdence interval
(CI)¼(0.8-8.9), p¼0.1. Survival probability from admission to 5 years was better for
AMI patients, 37.4%5.2% versus, 20.7%3.0% in non-AMI, HR¼1.5, CI¼(1.12-
2.0), p¼0.0067.
Conclusions: We observed a very favourable post-discharge prognosis in OHCA
patients undergoing on-admission CA with PCI if indicated. Patients suffering OHCA
due to AMI had better survival to discharge and at 5 years follow-up than patients
suffering OHCA due to other causes.TCT-256
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Background: It has been advocated that LTBL treatment in the context of p-PCI may
lead to unsuccessful angiographic reperfusion and unfavorable clinical outcome,
suggesting that thrombus aspiration should be considered in this subset. However, the
hazard of LTBL treatment on myocardial reperfusion and damage has not been
evaluated. This study aims to investigate the impact of large thrombus burden lesion
(LTBL) on myocardial damage, using CE-CMR in the setting of primary-PCI (p-PCI).
Methods: In 327 patients, who underwent p-PCI without mechanical device use,
within 12-hours from symptom onset, we prospectively assessed the impact of LTBL
on infarct size and microvascular damage, using CE-CMR. LTBL was deﬁned by the
presence of TIMI-thrombus score  3 in patent IRAs; or by “cut off” occlusion pattern
and/or large reference vessel diameter ( 3.5 mm) in occluded IRAs
Results: 197 (60.2%) patients showed LTBL, and 130 (39.8%) did not.
Distal embolization (DE) occurred in 18.8% LTBL vs 6.9% no-LTBL patients
(p¼0.003). At CE-MR, patients with LTBL had larger infarct size index (27.5+11.1
vs 22.1+17.5, p¼0.009), and more often transmural necrosis (70.5% vs55.4%,
p¼0.008) compared to patients without LTBL. After excluding patients with DE,
LTBL patients still had larger necrosis. At multivariate analysis, occluded (IRA) at
baseline, anterior infarction, and occurrence of distal embolization predicted trans-
mural necrosis.
Conclusions: Treatment LTBL in the setting of P-PCI is related to larger myocardial
damage as detected by CE-CMR, regardless of angiographic detectable embolization.
These ﬁndings suggest that in patients with LTBL thrombus aspiration before stenting
should be considered.TCT-257
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Background: Inappropriate activation (IA) of the cardiac catheterization laboratory
for code STEMI is associated with signiﬁcant time and health care costs. The clinical
outcome of patients with IA has not been characterized. The objective of this study
was to determine the reasons for IA and to evaluate the short-term outcome of these
patients.
Methods: From January, 2009 through September, 2011, 396 patients initially acti-
vated for code STEMI were evaluated. Patients that underwent emergent coronary
angiography with or without PCI were considered as appropriate activation (AA
Group, n ¼228); patients that were subsequently cancelled and did not undergo
emergent coronary angiography were considered as inappropriate activation (IAB84 JACC Vol 62/18/Suppl B j October 2Group, n¼168). Baseline demographics, ﬁndings of initial ECG, reasons for cancel-
lation and in-hospital outcome were collected.
Results: Mean age was 578 years and 73% were male. The most common initial
ECG ﬁndings for the IA group were ST segment elevation <1 mm (55%), arrhythmias
(23%), bundle branch block (22%) and left ventricular hypertrophy (18%). The most
common reasons for code STEMI cancellation were absence of ST segment elevation
>1 mm (83%), coexisting severe medical condition (10%) and a normal bedside
echocardiogram in the setting of an equivocal ECG (15%). In-hospital mortality was
signiﬁcantly worse for the IA Group compared to the AA Group, 17.3% vs 7%,
p¼0.002, respectively.
Conclusions: Abnormalities of rhythm and conduction and left ventricular hyper-
trophy account for the majority of ECG ﬁndings for IA. The lack of ST segment
elevation >1 mm was the most common reason for code STEMI cancellation. Short-
term mortality for patients with IA is signiﬁcantly higher than in patients with STEMI.
These ﬁndings suggest that additional treatment strategies for code STEMI cancel-
lation should be explored.TCT-258
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Background: Distal embolization (DE) is a serious complication of primary-PCI for
ST-elevation myocardial infarction, affecting mortality and morbidity rate. This study
aims to develop and validate a new angiographic risk score to predict the risk of DE in
patients undergoing p-PCI.
Methods: Study sample included data from 1200 pts undergoing p-PCI. Logistic
regression was used to examine the relationship between risk factors and occurrence
of DE. The cohort was randomly divided into a risk score development cohort
(n¼814), and a validation cohort (n ¼386). Each covariate in the model was assigned
an integer score based on the regression coefﬁcients.
Results: The rate of DE was 14.4%, with in-hospital mortality of 9.8%. At multi-
variate analysis, four variables resulted independent predictors of DE: the “cut-off ”
occlusion pattern of infarct-related artery, TIMI thrombus score 2-4, RVD  3.5
mm, lesion length > 20 mm. Each variable was assigned a 0 to +2 points according
to the strength of the statistical association. Risk scores 0 to 1 were considered low
risk, 2 to 4 intermediate risk, and 5 to 7 high risks for DE. DE was different among
risk score groups in both derivation cohort (p for trend < 0.0001; C-statistic 0.68)
and in validation cohort (p for trend <0.0001; C-statistic 0.64).Conclusions: The individual risk of distal embolization can be predicted using simple
4-variable model. The application of this new risk score can be useful in strategies
making during p-PCI in STEMI, particularly in selecting patients who may beneﬁt
from pharmacological and adjunctive mechanical thrombus removal.
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Background: Time to reperfusion treatment is known to be an essential predictor of
morbidity and mortality outcomes in patients with ST-elevation myocardial infarction
(STEMI). Speciﬁcally, increased door-to-balloon (DTB) time is associated with7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
PCI
(n=560)
CABG
(n=280)
P
value
1-month outcomes
MACE (death, MI, revascularization) 13.4% 15.4% 0.46
NACE (death, MI, revascularization, and major
bleeding)
19.1% 17.5% 0.45
All-Cause Mortality 2.1% 3.6% 0.22
Myocardial Infarction 10.2% 12.7% 0.33
Unplanned Revascularization 4.3% 1.4% 0.03*
Stroke 0.2% 0.7% 0.26
1-year outcomes
MACE 22.4% 19.7% 0.49
Death or MI 15.4% 16.4% 0.65
All-Cause Mortality 4.3% 4.7% 0.72
MI 12.7% 13.1% 0.88
Unplanned Revascularization 12.7% 5.2% 0.001*
TLR 8.5% n/a
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Sincreased mortality, irrespective of the presentation. Substantial patients with STEMI
experience no chest pain and are given a low priority score at the triage of emergency
department. We aimed to determine the impact of non-chest pain complaint
as a presenting symptom on the DTB time and clinical outcomes in patients with
STEMI.
Methods: A total of 11,417 STEMI patients who underwent primary PCI were
derived from the Korea Working Group on Myocardial Infarction from 2005 to 2012
and compared according to typical chest pain or non-chest pain complaint as a pre-
senting symptom. The primary outcomes were 12-month mortality and the composite
of major adverse cardiac events (MACE, deﬁned as death, non-fatal myocardial
infarction, and revascularization).
Results: Compared to patients with typical chest pain (n¼9,948, 87.1%), patients
with non-chest pain complaint (n¼1,469, 12.9%) were older, more female, and had
higher incidence of hypertension and diabetes, and also had higher incidence of
anterior infarct and higher Killip class. The time delay was also signiﬁcant in door-
to-laboratory arrival time (53 vs. 64 min, p<0.001), laboratory arrival-to-balloon
(20 vs. 23 min, p<0.001), and the DTB time (75 vs. 89 min, p<0.001). Non-chest
pain complaint was an independent determinant of the DTB time both in adjusted
models and in multivariate linear regression analysis. Patients with non-chest pain
complaint had more in-hospital death (4.1% vs. 11.5%, p<0.001), 12-month
mortality (6.5% vs. 16.3%, p<0.001), and the composite of MACE (12.2% vs.
22.5%, p<0.001).
Conclusions: The delays in identiﬁcation of STEMI and reperfusion treatment were
greater and associated with worse clinical outcomes in patients with non-chest pain
complaint as a presenting symptom. A triage using electrocardiogram should be
considered in these patients.Heparin + GPI
N=1532
Bivalirudin alone
N=1611 p value
30-days
Mortality 0.9% 1.5% 0.14
MI 5.8% 7.2% 0.0958
Urgent TVR 2.4% 2.1% 0.5720
NACE 13.5% 12.6% 0.4482
Composite ischemic outcome 8.2% 9.3% 0.3001
Non-CABG major bleeding 7.1% 4.1% 0.0002
1-year
Mortality 4.0% 3.8% 0.8293
Composite ischemic outcomes 17.4% 19.0% 0.0629TCT-260
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Background: Proximal LAD (pLAD) lesions are associated with increased cardio-
vascular risk in the setting of acute coronary syndrome (ACS). Surgical versus
percutaneous revascularization improves outcomes including mortality in complex
stable CAD. However, the impact of different revascularization strategies in ACS
patients with pLAD lesions remains unknown.
Methods: We performed a post-hoc analysis of patients in the ACUITY trial
(n¼13,819) presenting with a critical stenosis of the pLAD who underwent subse-
quent revascularization with a surgical or percutaneous approach (PCI). Major adverse
events comprised of death, myocardial infarction, repeat revascularization, stroke, and
bleeding were compared at 30 days and 1-year.
Results: Among the 842 patients we studied, revascularization was performed with
PCI and coronary artery bypass grafting (CABG) in n¼562 (67%) and n¼280 (33%)
respectively. Baseline clinical and angiographic characteristics were well balanced
between groups. Patients in the CABG group were more likely to undergo angiog-
raphy later than PCI (median time ﬁrst drug-angiography, 43 vs. 4 hours, P<0.01).
PCI was associated with an increase rate of revascularization at 1 month and 1 year,
without signiﬁcant difference in other clinical endpoints (Table 1).
Conclusions: Although surgical revascularization of proximal LAD during ACS
reduces further revascularization, it does not seem to improve the survival and MI
rates at 1-year compared with PCI.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-261
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Background: There are limited data on the effects of bivalirudin monotherapy
compared to standard antithrombotic therapy (heparin plus glycoprotein IIb/IIIa
inhibitor – GPI) on the outcomes of higher –risk acute coronary syndromes
(ACS) patients with positive biomarkers on admission. We examined the clin-
ical outcomes among positive biomarker patients undergoing percutaneous
coronary intervention (PCI) in the large-scale prospective, randomized ACUITY
trial.
Methods: The ACUITY trial was a multicenter, randomized trial assessing the
safety and efﬁcacy of bivalirudin alone or bivalirudin plus GPI vs. heparin plus
GPI among 13,819 patients with moderate and high-risk ACS, 7,789 of
whom underwent PCI. The in-hospital and 30-days primary endpoints were
composite ischemia (death, MI, or unplanned TVR for ischemia), Non-CABG
major bleeding, and net adverse clinical events (NACE¼composite ischemia or
major bleeding).
Results: A total of 4,728 PCI patients presented with a positive biomarker at the time
of admission. Of those, 1,532 were randomized to heparin plus GPI and 1,611 to
bivalirudin alone. There were no relevant baseline differences between treatment
groups regarding clinical proﬁle, TIMI risk score, antiplatelet medications and DES
use. Outcomes by treatment group at 30-days and 1-year are shown in the table. In
a multivariate model, use of bivalirudin was not a predictor of composite ischemic
outcomes up to one year (hazard ratio [95% CI]¼1.12 [0.97, 1.29], p¼0.1239), but
was associated with a reduction in major bleeding.acts/POSTER/STEMI/NSTEMI/ACS B85
